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AutophagyAutophagy involves multiple membrane trafﬁcking and fusion events. Annexin A7 (ANXA7) is postulated to
play a role in membrane fusion during exocytosis, while the contribution of ANXA7 to autophagy is poorly
understood. Our recent studies demonstrated that ABO could promote autophagy via elevation of ANXA7
and triggering ANXA7 subcellular redistribution. However, little is known about the molecular mechanisms
how ANXA7 regulates autophagy. As molecular disruption of ANXA7 in mice results in several unwished phe-
notypes, small molecule modulators may be efﬁcacious in deﬁning the mechanisms of ANXA7 action. How-
ever, so far no compounds that selectively target ANXA7 have been identiﬁed. So, we hypothesize that ABO
might be a potent modulator of ANXA7. We also have detected the colocalization of ANXA7 and
microtubule-associated protein 1 light chain 3 (LC3), and ANXA7 was essential for LC3 accumulation in
VEC autophagy. As a GTPase, whether ANXA7 affects the phosphorylation of LC3 or other proteins needs fur-
ther investigation. In this study, we performed site-directed mutagenesis and found that ABO directly bound
to Thr286 of ANXA7 and inhibited its phosphorylation. By yeast two-hybrid screening, we found that ANXA7
could interact with grancalcin (GCA). ABO promoted the interaction and inhibited GCA phosphorylation,
leading to the decrease of intracellular Ca2+ concentration. At the same time, ABO inhibited the phosphory-
lation of LC3. Hence, by identifying ABO as an unprecedented modulator of ANXA7 as well as GCA and LC3 as
interacting proteins of ANXA7, we demonstrated the possible mechanisms how ANXA7 regulates autophagy
for the ﬁrst time.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
ANXA7, a member of the annexin family of calcium-dependent
phospholipid binding proteins, codes for a Ca2+-dependent GTPase.
Several protein kinases, including PKC, cAMP-dependent protein kinase,
cGMP-dependent protein kinase, and pp60 c-src have been shown to
phosphorylate ANXA7 with high efﬁciency, while only PKC-dependent
phosphorylation has a signiﬁcant positive effect on ANXA7 GTPase [1].
It was reported that phosphorylation of ANX7 by PKC signiﬁcantly
potentiated the ability of the protein to fuse phospholipid vesicles inoxymethyl-1, 4-benzoxazine;
le-associated protein 1 light
tate 13-acetate; MMP, matrix
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l rights reserved.chromafﬁn cells [2]. Activation of PKC by PMA induces the secretion of
MMP-9, leads to activation of MMP-2, downregulates TIMP-1 and
TIMP-2 secretion, and increases membrane-type 1MMP on the cell sur-
face [3]. Thus, ANXA7 may be a positive mediator for PKC action in
secretion cascade. Furthermore, ANX7 is a newly described candidate
tumor suppressor gene for prostate cancer, as evidenced by a signiﬁ-
cantly higher rate of loss of ANX7 expression in metastatic and local re-
currences of hormone refractory prostate cancer as compared with
primary tumors [4]. ANXA7 exhibits many biological and genetic prop-
erties of a tumor suppressor gene and may play a role in carcinogenesis
through a discrete signaling pathway involving other tumor suppressor
genes, DNA-repair genes, and apoptosis-related genes [4,5]. Besides, in
our previous study and this study we showed, for the ﬁrst time to our
knowledge, that ANXA7 participated in autophagy [6]. A number of
studies have provided evidence of crosstalk between autophagy and
exocytosis. These reports have suggested that ANX7 plays several differ-
ent roles involved in exocytosis, autophagy, tumor suppression and
carcinogenesis.
However, the multiple roles of ANXA7 have made it difﬁcult to de-
ﬁne speciﬁc mechanisms by which the protein can contribute to a phe-
notype. To delineate the speciﬁc physiological function(s) of ANXA7,
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ANXA7 (−/−) mutation is lethal by E10 [7], and ANXA7(+/−) muta-
tion also has several unwished phenotypes, such as induce islet hyper-
plasia, β-cell hypertrophy, aberrant regulation of islet gene expression
by the fed/fasted state, and an alteration in the Ca2+-dependence of
glucose-induced insulin secretion [8]. As knockout mouse was not an
unideal model for ANXA7 research in disease, we reasoned that small
molecule modulators of ANXA7 may be efﬁcacious tools. Advances in
chemical genetics now allow us to identify small molecules that bind
to target proteins, and offer the opportunity to dissect the function of
the proteins [9]. Small molecules that modulate annexins, such as
withaferin A for annexin II, have been reported [10]; however, so far
no compounds that selectively target ANXA7 have been identiﬁed. Pre-
viously, we synthesized a series of 2, 3-dihydro-3-hydroxymethyl-1,
4-benzoxazine derivatives by tandem reduction-oxirane opening of
2-nitroaroxymethyloxiranes. Among the seven compounds (3a–g),
only ABO (3 g) remarkably inhibited the apoptosis of HUVECs [11].
Structural analysis showed that ABO has an amino-group at the
6-position, while other benzoxazine derivatives have chlorine atom(s)
or methyl-group at the 6 and/or 8-position of 2, 3-dihydro-1,
4-benzodioxine. Most relevant to this work, we also found that ABO
could promote autophagy via elevation of Ca2+ channel ANXA7 and
triggering ANXA7 subcellular redistribution [6]. All data suggested
that ABO might be a potent modulator of ANXA7, but the underlying
mechanism needs further investigation.
The major regulatory pathways promoting induction of autophagy
converge on the covalent lipidation of LC3. Like its yeast homologue
Atg8, LC3 is cleaved to liberate a C-terminal glycine needed for its
conjugation to phospholipids upon autophagy induction [12]. Recent
study identiﬁed a new phosphorylation site (serine 12) on LC3; phos-
phorylation of this site affects its interactions with phospholipids and
reduces its recruitment and participation in autophagy, while de-
phosphorylation allows cells to rapidly switch from basal to induced
autophagy [13]. As described previously, we have detected the
colocalization of ANXA7 and LC3, and ANXA7was essential for LC3 ac-
cumulation in VEC autophagy [6]. As a GTPase, whether ANXA7 is in-
volved in phosphorylation of LC3 attracts our interest.
2. Material and methods
2.1. Cell culture
COS7 cells were grown in DMEM (Gibco, 12800-017) with 10%
FBS (Hyclone, SV30087.02), penicillin (50 U/ml) and streptomycin
(50 μg/ml) (Invitrogen, 10378-016).
HUVECs were obtained as described by Jaffe et al. [14] and cultured
on gelatin-coated plastic dishes in M199 medium (Gibco, 31100-035)
supplemented with 10% heat-inactivated FBS and 10 IU/ml FGF-2 at
37 °C in a humidiﬁed incubatorwith 5%CO2. Passage number of HUVECs
for experiments ranged from passages 5 to 10.
2.2. Plasmid constructs and siRNAs
The coding region of human ANXA7 and GCA cDNAs was subcloned
into pEGFP-C2 and pMyc-C2 expression vector to produce pEGFP-
C2-ANXA7 and pMyc-C2-GCA constructs, respectively. T275A mutant
and T286A mutant (Thr275 and Thr286 of ANXA7 were mutated to
alanine, respectively) were subcloned into mCherry-N2 expression
vector as the wild-type ANXA7 cDNAs, which allowed us to measure
their location by ﬂuorescence assay. All of the constructs were con-
ﬁrmed by DNA sequencing. Cells were plated onto 6 cmdish at a densi-
ty 1 × 106/ml and grown for 24 h. When cell density reached 70–80%
conﬂuence, cells were transfected with indicated expression vectors
using Lipofectamine reagent (Invitrogen, 11668-019). 48 h after trans-
fection, cells were harvested and analyzed by western blot. To knock
down GCA expression, speciﬁc siRNAs against GCA (Santa Cruz,sc-43349) were purchased from Santa Cruz Biotechnology, while
speciﬁc siRNAs against ANXA7 were obtained from Invitrogen. When
cell density reached 50–60% conﬂuence, siRNA against GCA or ANXA7
or scrambled RNA (negative control, Santa Cruz, sc-37007) were
transfected into VECs with RNAiFect Transfection Reagent (Qiagen,
1022076) according to the manufacturer's protocol, and cell lysates
were collected for western blot 2 days after transfection.
2.3. Immunoprecipitation
COS7 cells or HUVECs were washed with ice-cold PBS and lysed in IP
buffer (Beyotime, P0013) containing 150 mM NaCl, 20 mM Tris–HCl
(pH 7.5), 1% TritonX-100, andproteinase inhibitormix. After centrifuging
at 4 °C, the supernatant was collected and precleared with protein A/G
agarose beads (Beyotime, P2012) for 1 h at 4 °C. The supernatant
was collected after centrifuging and incubated with speciﬁc antibod-
ies or normal mouse IgG (as control), followed by incubation with
Protein A/G beads overnight at 4 °C. The beads were washed three
times with IP buffer and then eluted with 2 × SDS loading buffer.
The immunoprecipitated proteins were detected by western blot
assay.
2.4. Western blot
Following separated by SDS-PAGE and transfered to PVDF mem-
brane (Millipore, IPVH00010), proteins were probedwith primary anti-
bodies, then horseradish peroxidase-linked secondary antibodies, and
detected with the use of an enhanced chemiluminesence detection kit
(Thermo Fisher, 34080). The relative quantity of proteins was analyzed
by Quantity one software and normalized to loading controls.
2.5. Immunocytochemistry
HUVECs were ﬁxed in 4% paraformaldehyde (w/v) for 30 min at
room temperature and blocked in 1× PBS, 0.01% Triton X-100 (v/v)
and 5% goat serum (v/v). Cells were subsequently incubated with rab-
bit anti-human ANXA7 antibody and mouse anti-human GCA anti-
body overnight at 4 °C. Then cells were rinsed in 1× PBS 3 times
and incubated with Alexa Fluor 543 goat anti-rabbit and Alexa Fluor
633 goat anti-mouse IgG for 1 h at 37 °C. For negative controls, cells
were incubated with normal IgG. Fluorescence images were obtained
using an inverted microscope (Zeiss Axio Observer A1). Carl Zeiss
AxioVision 4.6 software was used to measure the ﬂuorescence inten-
sity, which was measured in at least 6 regions for each labeling con-
dition, and representative results were shown.
2.6. Antibodies
Antibodies for ANXA7 (Santa Cruz, sc-11389, sc-17815), GCA (Santa
Cruz, sc-14224) and horseradish peroxidase-conjugated secondary an-
tibodies were purchased from Santa Cruz Biotechnology. Antibodies
for GFP (Cell Signaling Technology, 2956), and LC3 (Cell Signaling
Technology, 2775) were purchased from Cell Signaling Technology. An-
tibodies formCherry (Abcam, 125096), and cMyc (Abcam, 11917)were
obtained from Abcam. Phospho-LC3C-S12 antibody (Abgent, AP3301a)
[13] and a custom phospho-GCA-S168 antibody were obtained from
Abgent. Secondary antibodies for immunoﬂuorescence were goat
anti-rabbit IgG Alexa Fluor-549 (Invitrogen, A-11037), goat anti-rabbit
IgG Alexa Fluor-633 (Invitrogen, A21071), and goat anti-mouse IgG
Alexa Fluor-488 (Invitrogen, A11029).
2.7. Yeast two-hybrid screen
Brieﬂy, full length of human ANXA7 cDNA was cloned into yeast
expression vector pGBKT7 (Clontech, 630489) to express the bait pro-
tein. The yeast strain AH109 (Clontech, 630444) was sequentially
Fig. 1. ABO targeted ANXA7. A, Chemical structures of ABO, 6-amino-2,3-dihydro-
3-hydroxymethyl-1,4-benzoxazine. B, Equal amounts of HUVEC lyses were incubated
with ABO at indicated concentrations, and then immunoprecipitated using ANAX7 anti-
bodies. Western blots of immunoprecipitations (IPs) with ANAX7 showed a dose-
dependent inhibition in the interaction between ANXA7 and its antibody. *p b 0.05,
**p b 0.01, ***p b 0.001 vs.withoutABO-treatedgroup, n = 3. C,HUVECswere transfected
with expression vectors Cherry-N2 and Cherry-N2-ANXA7 using TurboFectin 8.0 transfec-
tion reagent (Origene). 48 h after transfection, cells were harvested. Equal amounts of in-
dicated cell lysate proteins were immunoprecipitated using cherry antibodies. Western
blots of IPs with ANXA7 antibodies showed that the level of Cherry-N2-ANXA7
immunoprecipitated by Cherry antibodies was unchanged with ABO treatment. N.S., no
signiﬁcant difference, n = 3.
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on pACT2 vector (Clontech, 638822). Totally, 3.7 × 106 transformants
were selectively screened using HIS3 (at the presence of 2.5 mM of
3-amino-1,2,4-triazole) as the primary reporter gene, then two more
reporter genes ADE2 and lacZwere used to verify the positive colonies.
The prey vectors in triple-positive yeast colonies were recovered and
cDNA inserts were sequenced.
For further validation of the interaction between ANXA7 and the
candidate proteins, pGBKT7-ANXA7 and the library plasmids encoding
the interacting partners were retransformed into AH109, and the acti-
vation of reporter genes was examined.
2.8. Determination of intracellular calcium concentration
Intracellular calcium concentration was determined as described
before [6]. Brieﬂy, after treatmentwith siRNAor ABO, cellswerewashed
3 times and incubatedwith 10 μMFluo-3 AM (Invitrogen, F-14218) and
0.02% Pluronic F127 (Invitrogen, P6866) in basicM199medium at 37 °C
for 30 min in the dark, then washed 3 times and cultured for another
30 min at room temperature. The ﬂuorescence of Fluo-3 AMwas excit-
ed with an excitation wavelength of 488 nm and ﬂuorescence signals
were collected with emission wavelength of 515–550 nm by a laser
scanning confocal microscope (Leica, TCS SP2). Data were analyzed
with Leica Confocal Software.
2.9. Statistical analyses
Data are expressed asmean ± SEM. SPSS 11.5 (SPSS Inc., Chicago, IL)
was used for statistical analysis. Datawere analyzed by one-way ANOVA
(followed by Scheffé F test for post-hoc analysis). A p b 0.05was consid-
ered statistically signiﬁcant.
3. Results
3.1. ABO directly binds to ANXA7
To investigate the mechanism how ABO (Fig. 1A) regulates ANXA7
and ultimately promotes autophagy, we ﬁrst examined the interac-
tion of ABO and ANXA7. We used a monoclonal antibody that specif-
ically recognizes ANXA7's C-terminal sequence to immunoprecipitate
ANXA7 and examine whether ABO can interfere with this process.
The results showed that ABO blocks the binding of ANXA7 with this
antibody in a dose-dependent way (Fig. 1B). We could not see this ef-
fect when we used an anti-mCherry antibody to immunoprecipitate
mCherry-ANXA7 fusion protein expressed in HUVECs, suggesting
that ABO might bind to the C-terminus of ANXA7 directly (Fig. 1C).
3.2. ABO inhibits the phosphorylation of ANXA7
We then examined whether binding of ABO could affect the
phosphorylation status of ANXA7. Immunoprecipitated ANXA7 was
subjected to western blot using antibodies against different phosphory-
lation amino acid residues. The results showed that ABO-treated cells
showeddecreased phosphorylation of ANXA7 at the threonine residues,
but not the serine or tyrosine residues (Fig. 2A). To test whether
decreased phosphorylation or increased dephosphorylation results in
decreased reactivity with p-thr antibodies, we used NaF, a broad speci-
ﬁcity inhibitor of serine/threonine phosphatase [15,16]. The results
showed that, both in the absence and presence of NaF, ABO could signif-
icantly decrease the phosphorylation level of ANXA7, suggesting that
ABO inhibited ANXA7 phosphorylation rather than increasing ANXA7
dephosphorylation [Supplementary Fig. 1]. It has been reported that
PKC increases phosphorylation of ANXA7 at the serine and threonine
residues, and sequence and site-directed mutagenesis studies have
shown that putative binding sites for GTP are located in proximity to
consensus phosphorylation sites for PKC [1]. We focused on Thr275and Thr286, which may be the GTP binding sites on ANXA7, and
performed site-directed mutagenesis as T275A and T286A. Then, we
expressed Cherry-N2-ANXA7- mutant 1(T275A) and Cherry-N2-
ANXA7- mutant 2 (T286A) in HUVECs and examined their phosphory-
lation status. The results showed that ABO inhibited the phosphoryla-
tion at the threonine residues, while T286A almost completely
abolished phosphorylation (Fig. 2B). Notably, the T286A mutant form
of ANXA7 showed decreased relocalization of ANXA7 induced by ABO
(Fig. 2C). Our data support a possibility that ABOmight inhibit the bind-
ing between ANXA7 and GTP, which could confer conformational ﬂexi-
bility that may make ANXA7 phosphorylation sites more accessible to
protein kinases, substantially inhibit its phosphorylation and GTPase
activity.3.3. GCA interacts with ANXA7
In order to identify ANXA7-interacting partners that may be in-
volved in ABO-induced autophagy, we screened a human cDNA li-
brary for proteins interacting with ANXA7 by yeast two-hybrid
screening. Among the several possible ANXA7-interacting proteins
identiﬁed, GCA attracted our attention. GCA belongs to the penta-
Fig. 2. ABO inhibited ANXA7 phosphorylation at Thr286 in HUVECs. A, HUVECs were incubated for 1 h without or with 50 μM ABO and the immunoprecipitates (IPs) were obtained
with ANXA7 antibodies. Western blots of IPs with indicated antibodies showed that ABO inhibited ANXA7 phosphorylation at the threonine residues (Thr). **p b 0.01 vs. Control
(Ctr), n = 3. B–C, HUVECs expressing Cherry-N2, Cherry-N2-ANXA7, Cherry-N2-ANXA7-mt1 (T275A) and Cherry-N2-ANXA7-mt2 (T286A). B, HUVECs were harvested in lysis buff-
er and equal amounts of cell lysate proteins were immunoprecipitated using ANXA7 antibodies. Western blots of IPs with ANXA7 and p-Thr antibodies showed equal levels of
ANXA7 but decreased reactivity with p-Thr antibodies in ABO treated group and Cherry-N2-ANXA7-mt2 (T286A) group in comparison to the Cherry-N2-ANXA7 group.
*p b 0.05, **p b 0.01 vs. Cherry-N2-ANXA7 group, n = 3. C, Fluorescence images were shown for each agent. Expression of the T286A mutant form of ANXA7 diminished the
relocalization of ANXA7 induced by ABO. Bar represents 16 μm. Quantiﬁcation of the number of ANXA7 fusion protein dots per cell was shown for each agent. *p b 0.05, n = 3.
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sorcin, peﬂin, and ALG-2, and shares the same important function of
Ca2+ binding [17]. Previous studies have shown that ANXA7 interacts
with two members of this family: sorcin and ALG-2 [18,19]. The inter-
action between ANXA7 and GCA was conﬁrmed in COS7 cells and
VECs by co-immunoprecipitation experiments (Fig. 3A–C).
We then performed the following experiments to examine whether
ABO could affect the interaction between ANXA7 and GCA. Firstly,
HUVECs were treated with ABO for 6 h and 12 h respectively. The
cells were lysed, and the supernatant was immunoprecipated with
anti-GCA IgG and agrose A + G beads overnight at 4 °C. Western blot
analysis showed that ABO could promote the interaction of ANXA7
and GCA in the cells (Fig. 3B). Secondly, HUVECswere lysed, and the su-
pernatant was divided into three parts, followed by incubation with or
without ABO in the presence of anti-GCA IgG and agrose A + G beadsovernight at 4 °C. The co-immunoprecipitation results showed
that ABO enhances the interaction of ANXA7 and GCA (Fig. 3C).
Thirdly, immunoﬂuorescence analysis showed that ABO promoted
the co-localization of ANXA7 and GCA in HUVECs (Fig. 3D).3.4. GCA is involved in VEC autophagy induced by ABO
We then moved on to examine whether GCA is involved in autoph-
agy by knocking down GCA expression with siRNA in HUVECs (Fig. 4A).
The results showed that knockdown of GCA does not affect the level of
ANXA7, while the intracellular Ca2+ concentrationwas dramatically el-
evated (Fig. 4A and B), and ABO could not depress the Ca2+ level and
could not induce autophagy anymore (Fig. 4B–D), suggesting that GCA
indeed acts downstream of ABO and ANXA7 in regulating autophagy.
Fig. 3. GCA interacted with ANXA7 and ABO promoted the interaction in HUVECs. A, ANXA7 bound to GCA in COS7 cells. Co-immunoprecipitation (Co-IP) of GFP-tagged ANXA7
proteins with Myc-tagged GCA from COS7 cells transfected pEGFP-C2-ANXA7 with pMyc-C2 (lane 1) or Myc-C2-GCA (lane 2). The lower panel showed expression levels of
EGFP-C2-ANXA7 and Myc-C2-GCA in the experiment. B–D, ABO promoted the interaction of ANXA7 and GCA in HUVECs. B, Co-IP of ANXA7 with GCA from HUVECs treated with
DMSO or 50 μM ABO for indicated times. Co-immunoprecipitated ANXA7 was quantiﬁed in immunoblot with anti-ANXA7 antibody in western blot (WB). *p b 0.05 vs. without
ABO treatment group, n = 3. C, HUVECs were lysed, and the supernatant was divided into three parts, followed by incubation with or without ABO. Co-immunoprecipitated
ANXA7 was quantiﬁed in immunoblot with anti-ANXA7 antibody in western blot (WB). *p b 0.05 vs. without ABO treatment group, n = 3. D, Double immunohistochemical stain-
ing showed that ANXA7 (red) and GCA green) exhibited agglomeration and colocalization after ABO treatment for12 h in HUVECs. Overlays of the red and green signal with a yel-
low colour indicated co-localization. Bar represents 16 μm. The bar chart shows quantiﬁcation of co-localization of ANXA7 and GCA. *p b 0.05 vs. control, n = 3.
Fig. 4. GCA participated in VEC autophagy induced by ABO. A, For GCA interference strategy, cells were subjected to 40 nM scrambled siRNA or 20 nM or 40 nM GCA siRNA for 6 h
and cultured for 24 h. Western blot analysis veriﬁed GCA silencing efﬁciency and showed that knockdown of GCA did not affect the level of ANXA7. 40 nM GCA siRNA was used in
subsequent experiments. **p b 0.01 vs. scrambled group (Scr), #p b 0.05, n = 3. B, Knockdown of GCA dramatically elevated the intracellular Ca2+ concentration. Simultaneously,
ABO could not depress the Ca2+ level. Bar represents 32 μm. *p b 0.05, N.S., no signiﬁcant difference, n = 3. C, Immunostaining of LC3 in subconﬂuent HUVECs subjected to scram-
bled siRNA (Scr) or GCA siRNA. Bar represents 16 μm. The percentage of cells containing LC3 puncta (>5) was calculated. *p b 0.05 vs. ABO-untreated group, N.S., no signiﬁcant
difference, n = 3. D, Western blot analysis of protein level of LC3-II. *p b 0.05, N.S., no signiﬁcant difference, n = 5.
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It has been reported that Ser168 may be a phosphorylation site of
GCA [20], we then investigated whether ANXA7 regulates the phos-
phorylation of GCA. Our results showed that ABO-treatment causes
decreased phosphorylation of GCA at the serine residues (Fig. 5A).
Furthermore, ANXA7 interference strategy was performed (Fig. 5B).
As shown in Fig. 5C, ANXA7 knockdown did not affect the total level
of GCA, but almost completely inhibited the phosphorylation of
GCA. Then, phospho-GCA-S168 antibody was used to test the effects
of ABO and ANXA7 on the phosphorylation of GCA at Ser168. The re-
sults showed that, both in the absence and presence of NaF, ABO
could signiﬁcantly decrease the phosphorylation level of GCA,
suggesting that ABO inhibited GCA phosphorylation rather than in-
creasing GCA dephosphorylation [Supplementary Fig. 2]. Compared
with ABO treatment, ANXA7 knockdown cause a steady state decline
in GCA phosphorylation [Supplementary Fig. 3].
Since LC3 has been shown to play a central role in different types
of autophagy, we investigated whether LC3 phosphorylation was reg-
ulated by ABO or ANXA7. The results showed that the levels of phos-
phorylated LC3 were decreased by treatment with ABO for 12 h or
ANXA7 knockdown (Fig. 5D). Also, both in the absence and presence
of NaF, ABO could signiﬁcantly decrease the phosphorylation level ofFig. 5. ANXA7 regulates the phosphorylation of GCA and LC3. A, HUVECs treated with ABO
were immunoprecipitated using GCA antibodies. Western blots of IPs with p-Ser and GCA a
6 h time point in ABO-treated group in comparison to the controls. **p b 0.01 vs. control, n =
of ANXA7 designed by Invitrogen, siRNA-16 had the best efﬁciency in knockdown of ANXA7
experiments. HUVECs treated with ABO or DMSO (Control, Ctr) for 6 h (C) or 12 h (D). For A
ANXA7 siRNA-16 for 6 h and cultured for 24 h. HUVECs under indicated treatments were har
using GCA antibodies. Western blots of IPs with p-Ser and GCA antibodies showed equal leve
ANXA7 siRNA group in comparison to the controls. D, Western blot of cell lysate proteins p
loading control. **p b 0.01 vs. control, ##p b 0.01 vs. scrambled group (Scr), n = 3.LC3, suggesting that ABO inhibited LC3 phosphorylation rather than
increasing LC3 dephosphorylation [Supplementary Fig. 4].
4. Discussion
In our previous study and in this study, we found that ABO induced
ANXA7-dependent autophagy via regulating the protein level, dis-
tribution and phosphorylation of ANXA7. ABO could induce ANXA7 re-
distribution and inhibit ANXA7 phosphorylation during a short-term
incubation and elevate the protein level of ANXA7 during a long-term
incubation, suggesting that the change of ANXA7 distribution and phos-
phorylationmay occur during the autophagy progressing, while ANXA7
elevation is the causation of autophagy stimulation. We hypothesize
that elevated ANXA7 level induces autophagy, which needs the mem-
brane compartmentation for autophagosome formation; ANXA7 might
function in the process of membrane compartmentation. But this needs
further clariﬁcation.
It has been shown that ABO could trigger ANXA7 subcellular redis-
tribution and facilitate the colocalization of ANXA7 with LC3 [6]. This
study reinforced the previous conclusions, as we found that LC3 serves
as an interacting protein for ANXA7. Notably, in our previous studies,
we showed that overexpression ANXA7 was sufﬁcient to induce
LC3-II accumulation, while lowered levels of LC3-II were detected inor DMSO (Control, Ctr) for 3 h, 6 h, 12 h or 24 h. Equal amounts of cell lysate proteins
ntibodies showed equal levels of GCA but decreased reactivity with p-ser antibodies at
3. B, Western blot analysis veriﬁed ANXA7 silencing efﬁciency. Among the three siRNA
. **p b 0.01 vs. scrambled group (Scr), n = 3. 40 nM siRNA-16 was used in subsequent
NXA7 interference strategy, cells were subjected to 40 nM scrambled siRNA or 40 nM
vested in lysis buffer. C, Equal amounts of cell lysate proteins were immunoprecipitated
ls of GCA but decreased reactivity with p-Ser antibodies both in ABO-treated group and
robed with phospho-LC3C-S12 antibody, total LC3 antibody, and GAPDH antibody as a
2098 H. Li et al. / Biochimica et Biophysica Acta 1833 (2013) 2092–2099ANXA7-deﬁcient cells (also was shown in Fig. 5D). We assumed that
ANXA7, as a phospholipid-binding protein,might serve as a phospholip-
id source for LC3-phospholipid conjugation reactions, but this needs fur-
ther elucidation.
As aGTPase, ANXA7hydrolyzesGTP in several intracellular trafﬁcking
steps [1]: (1) The binding of GTP to ANXA7 confers conformational ﬂex-
ibility that makes ANXA7 phosphorylation sites more accessible to pro-
tein kinases; (2) ANXA7 phosphorylation by protein kinases; (3) GTP
binding and GTP hydrolysis. There are several questions that need to be
investigated in the future. As PKC-dependent phosphorylation has a sig-
niﬁcant positive effect on ANXA7 GTPase and ABO could inhibit ANXA7
phosphorylation along with the decrease of ANXA7 GTPase activity,
ABO might inhibit the ANXA7 phosphorylation induced by PKC, but its
underlying mechanism needs further research. Whether the binding of
ABO to ANXA7 could confer conformational ﬂexibility that makes it
more accessible to other proteins, such as GCA and LC3 and how ABO
affects ANXA7 at the intersection of the pathway for exocytosis and
autophagy. Further evidence concerning these mechanisms is expected
from ANXA7 crystal structure, which would allow a better elucidation
of the conformational changes induced by GTP and ABO.
We found that GCAmight be involved in VEC autophagy for the ﬁrst
time. However, at present it is unclear whether there is a crosstalk
between Ca2+ binding function and phosphorylation of GCA. Previous
studies have shown that the potential phosphorylation site of GCA
was in the third Ca2+-binding region, which further emphasizes the
possibility of multiple, mutually non-exclusive mechanisms underlying
GCA-dependent intracellular free Ca2+ level regulation.
Increasing evidence suggests that Ca2+ homeostasis is critical for
autophagosome formation [21]. However, the relationship between
Ca2+ and autophagy has not been fully elucidated. It was reported
that the increase of intracellular Ca2+ could induce accumulation of
autophagosomes inMCF-7 andHeLa cells, while L-type Ca2+ channel an-
tagonist facilitated autophagosome formation in COS-7 cells via reducing
intracellular Ca2+ [22]. These data indicated that the changes of intracel-
lular Ca2+ level could lead to opposite effects on autophagy, depending
on cell type or cellular state. From a recent review paper, we understand
that the basal Ca2+ signal does not promote autophagy, while reducing
this Ca2+ signal leads to autophagy. However, when the Ca2+ signaling
becomes continuously reduced in extreme cases, the cells eventually un-
dergo apoptosis. On the other hand, increasing the Ca2+ signal by
thapsigargin or ionomycin will stimulate autophagy, although free Ca2+
at very high concentrations will increase Ca2+-uptake by mitochondria,
thereby promoting apoptosis [23]. In our previous study, we found that
ABO induced ANXA7-dependent autophagy and reduced the intracellular
free Ca2+ level [6]. In the current study,we found that knockdownofGCA
dramatically elevated the intracellular Ca2+ concentration, at this time,
ABO could not depress the Ca2+ level and failed to induce autophagy,
suggesting that GCA was important in ABO-induced autophagy.
Accumulating evidence suggested that autophagy is involved in var-
ious diseases, including neurodegeneration, cancer and atherosclerosis
[24]. Enhancement of autophagymay bring potential beneﬁts to clinical
therapy. As an example, in advanced atherosclerotic plaques, moderate
autophagy safeguards plaque cells against cellular distress, in particular
oxidative injury, by degrading damaged intracellular material. In addi-
tion, we have previously reported that ABO, as a protector of VECs,
could avert vascular VEC apoptosis induced by nutrient deprivation
[11] and oxLDL [25], which has been assumed as amajor cause of endo-
thelial dysfunction associated with proatherogenic conditions [26].
However, whether ABO has beneﬁcial effects and whether ANXA7 in-
hibits atherosclerosis progression in vivo by inducing autophagy in
ECs needs further investigation.
5. Conclusion
In this study, we identiﬁed ABO as an unprecedented modulator of
ANXA7. ABO could directly bind to ANXA7 and inhibit its phosphorylation,leading to inhibition of GCA and LC3 phosphorylation, and promotion of
autophagy. By identifying ABO as a modulator of ANXA7, as well as GCA
and LC3 as interacting proteins of ANXA7, we demonstrated the possible
mechanisms underlying ANXA7 regulating autophagy for the ﬁrst time.
Furthermore, as a small molecule modulator of ANXA7 function, ABO
provides a tool to study the complex cellular functions of ANXA7.
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